hVIVO PLC to Showcase Insights at Jefferies London Healthcare Confer...

Highlights:,hVIVO CEO, Yamin 'Mo' Khan, will present at the Jefferies Healthcare Conference in London on 19 November 2024 at 12:00pm GMT.,The Jefferie...

International Biotechnology Trust Reports Strong NAV Growth and Stra...

Highlights,Strong NAV Performance,: NAV rose 15.9%, outperforming the NASDAQ Biotechnology Reference Index’s 15.3% gain.,Strategic Investment Gains,:...

Spire Healthcare’s Buyback of Shares Successfully Completed

Highlights:,Spire Healthcare has repurchased 50,000 of its ordinary shares on the London Stock Exchange.,The share repurchase forms part of the compan...

Ondine Biomedical Launches £8.5 Million Fundraising Effort for U.S....

Highlights,Fundraising targets at least £8.5 million to fund a U.S. Phase 3 clinical trial for Ondine’s nasal photodisinfection technology.,A 36% incr...

Smith+Nephew Q3 2024 Trading Update: Revenue Growth Moderates Amid C...

Highlights,Q3 revenue rose 4% YoY to $1,412 million, with strong growth outside China.,Orthopaedics, Sports Medicine, and Advanced Wound Management se...

Avacta Therapeutics Showcases Next Generation of pre|CISION® Medicin...

Highlights,Avacta Therapeutics hosted a live R&D Spotlight event in London, focusing on its next-generation peptide drug conjugates (PDC) aimed at tar...

GSK Adjusts Vaccine Sales Forecast as Q3 Holds Steady, Analysts See...

Highlights:,Vaccine Sales Fall Short:,Arexvy and Shingrix sales missed forecasts, leading to a second downgrade in GSK’s vaccine segment.,Overall Grow...

GSK Maintains Positive Trajectory for 2024 Amid R&D Advances

Highlights,GSK's Q3 2024 sales reached £8.0 billion, reflecting a 2% decline at actual exchange rates (AER) but a 2% increase at constant exchange rat...

Eli Lilly Shares Fall as Company Lowers Year-End Guidance After Q3 R...

Highlights:,Lowered Annual Guidance:,Eli Lilly reduced its earnings forecast to $13.02–$13.52 per share, down from $16.10–$16.60.,Zepbound,Sales Miss...

A decline in full year 2024 earnings is noted by Bioventix

Highlights,Bioventix reported a 6.2% increase in revenue for FY 2024, totaling £13.6 million, despite missing analyst estimates.,Net income decreased...

GSK sees a rise in quarterly sales, and Next enhances its full-year...

Highlights,GSK reported a 2% increase in constant exchange rate sales to £8 billion, driven by growth in specialty medicines despite a decline in vacc...

Hemogenyx Pharmaceuticals PLC outlines the schedule for its Phase I...

Highlights,Hemogenyx Pharmaceuticals plc has announced the schedule for launching its Phase I clinical trial for HEMO-CAR-T (HG-CT-1), targeting relap...

Strong Q3 Results Boost Shield Therapeutics’ Financial Health Ahead...

Highlights:,Shield Therapeutics (LSE:STX) reports robust Q3 revenue, driven by increased demand for Accrufer.,The company secures additional financing...

Olympus Hit by Leadership Crisis as CEO Steps Down Amid Drug Scandal

Highlights:,Olympus CEO Stefan Kaufmann resigned after an internal probe into allegations of illegal drug purchases.,Kaufmann, the second non-Japanese...

Three UK Stocks Highlighted for Possible Undervaluation of Up to 40....

Highlights,Market Downturn,: The UK stock market, including the FTSE 100 and FTSE 250, has faced recent declines influenced by weak trade data from Ch...

Avacta Showcases Promising Preclinical Results for AVA6103 and AVA71...

Highlights,Targeted Tumor Therapy,: AVA6103 and AVA7100 demonstrated strong preclinical results, focusing on tumor-specific drug delivery through FAP...

Syncona’s Spur Therapeutics Reports Promising Phase I/II Data for FL...

Highlights,Positive Phase I/II Results for FLT201,: Spur Therapeutics presented encouraging data from the GALILEO-1 study, where five out of six patie...

Scancell Holdings (AIM) Names Dr. Phil L'Huillier as CEO, Boosting D...

Highlights:,Dr. Phil L'Huillier appointed as CEO of Scancell (LSE), bringing extensive biotech expertise.,Current CEO, Professor Lindy Durrant, transi...

Earnings Performance of Genus (LON:GNS) Shows Promising Signs

Highlights:,Genus plc reported weak earnings recently, but a deeper analysis suggests the results may not fully reflect the company’s profitability po...

Genflow Biosciences (LSE:GENF) Secures €4 Million Funding to Advance...

Highlights:,Genflow Biosciences (LSE:GENF) secures over €4 million in funding from Wallonia to advance its lead gene therapy, GF-1002.,The package inc...